companies amneal-pharmaceuticals-inc 
LexBlog IP
OCTOBER 4, 2022
Yesterday, Amneal Pharmaceuticals, Inc. As we previously reported , Amneal’s biosimilar was developed in collaboration with Spain-based biopharmaceutical company mAbxience. According to Co-Chief Executive Officers Chirag and Chintu Patel, “Amneal has officially entered the U.S. biosimilar market.
Fish & Richardson Trademark & Copyright Thoughts
JANUARY 11, 2022
Several other companies have also announced plans to pursue interchangeable status for biosimilar products. Consistent with this, as shown below in Table 2, numerous companies have publicly announced the submission and/or acceptance of new biosimilar BLAs. Amneal / mAbxience). BLA Accepted: October 4, 2021. ranibizumab.
Expert insights. Personalized for you.
52 
Let's personalize your content